In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Dealmaking Statistics, Q4 2016

A look at financing, M&A and alliance activity October–December 2016

Executive Summary

Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.

Advertisement

Related Content

Early Stage Biopharma Financings Kept Up Multibillion-Dollar Pace In 2016
New Parent Lonza Welcomes Capsugel's Independent Streak To Innovate
Prestige Brands Acquires C.B. Fleet, Boosts Women’s OTC Platform
Broad-Based Incyte/Merus Collaboration Includes Up To 11 Bispecific Antibody Programs
Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
Astellas Grows Oncology Portfolio With Ganymed Purchase
Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors
Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations
Allergan Licenses MEDI2070, As AstraZeneca Continues Non-Core Exits

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel